


INFORMAZIONI PERSONALI



Dr. Elia Sechi

 Azienda Ospedaliero Universitaria di Sassari
S.C. Clinica Neurologica
Viale San Pietro, 10; 07100 Sassari (Italy)

H-Index on Scopus: 24

Ultimo aggiornamento: 18 maggio 2024

FORMAZIONE e POSIZIONI
LAVORATIVE

Gennaio 2021- Oggi **Dirigente medico Neurologo**
S.C. Clinica Neurologica
AOU Sassari, Sassari (Italia)

Giugno 2017- Gennaio 2021 **Clinical Research Fellowship in Autoimmune Neurology and Multiple Sclerosis**
Mayo Clinic, Rochester, MN (USA)
Mentor: E.P. Flanagan

Giugno 2017- Ottobre 2019 **Master in Biomedical Sciences - Clinical and Translational Science**
Mayo Clinic, Rochester, MN (USA)
Mentor: S.J. Pittock

Agosto 2013 - Agosto 2018 **Specializzazione in Neurologia**
Università degli studi di Sassari, Sassari (Italia)
Voto finale: 50/50 cum laude

Settembre 2006 - Ottobre 2012 **Laurea Magistrale in Medicina e Chirurgia**
Università degli stidu di Sassari, Sassari (Italia)
Voto finale: 110/110 cum laude

Giugno 2022 **Abilitazione Scientifica Nazionale a Professore di II Fascia**
Settore 06/D6 – Neurologia
Bando D.D. 553/2021

Marzo 2020 - Gennaio 2021 **Assistant Professor of Neurology (RTDB)**
Mayo Clinic College of Medicine
Mayo Clinic, Rochester, MN (USA)

TITOLI E POSIZIONI
ACCADEMICHE

ABILITA' PERSONALI

Lingua madre Italiano

Altre lingue

	COMPRESIONE		PARLATO		SCRITTURA
	Linguaggio parlato	Letture	Conversazione	Lessico e grammatica	
Inglese	C2	C2	C2	C2	C2

[Documenti correlati:](#)

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2: Proficient user
[Common European Framework of Reference for Languages](#)

Abilità strumentali/informatiche

Conoscenza avanzata di Microsoft® Office (Word, Excel, PowerPoint)
Conoscenza avanzata di JMP® Pro

Ambito di interesse/
super-specializzazione

Patologie infiammatorie/autoimmune del SNC, NMOSD, MOGAD; sclerosi multipla, mielopatie

PUBBLICAZIONI

Pubblicazioni su riviste
internazionali

1. Keegan BM, Messina SA, Hanson D, Holmes D, Camp J, **Sechi E**, Nayak S, Barakat B, Ahmad R, Mandrekar J, Harmsen WS, Kantarci O, Weinschenker BG, Flanagan EP. *MR Imaging Features of Critical Spinal Demyelinating Lesions Associated with Progressive Motor Impairment*. AJNR Am J Neuroradiol 2024. doi: 10.3174/ajnr.A8304
2. **Sechi E**, Deiana GA, Puci MA, Zara P, [...] Sotgiu G, Solla P. *Epidemiology of seropositive myasthenia gravis in Sardinia: A population-based study in the district of Sassari*. Muscle Nerve 2024; 69(5):637-642.
3. **Sechi E**, Puci MA, Patteri MI, [...] Cocco E, Frau J. *Epidemiology of aquaporin-4-IgG-positive NMOSD in Sardinia*. Mult Scler Relat Disord 2024; 85:105522. doi: 10.1016/j.msard.2024.105522.
4. Budhram A, **Sechi E**. *Antibodies to neural cell surface and synaptic proteins in paraneoplastic neurologic syndromes*. Handb Clin Neurol 2024; 200:347-364.
5. McCombe JA, **Sechi E**, Zekeridou A. *Neurologic manifestations of autoimmunity with immune checkpoint inhibitors*. Handb Clin Neurol 2024; 200:449-465.
6. Simula ER, Zarbo IR, Arru G, **Sechi E**, Melori R, Deiana GA, Solla P, Sechi LA. *Antibody Response to HERV-K and HERV-W Envelope Epitopes in Patients with Myasthenia Gravis*. Int J Mol Sci 2023;25(1):446.
7. Zara P, Dinoto A, Carta S, Floris V, Turilli D, Budhram A, Ferrari S, Milia S, Solla P, Mariotto S, Flanagan EP, Lopez Chiriboga AS, **Sechi E**. *Non-demyelinating disorders mimicking and misdiagnosed as NMOSD: a literature review*. Eur J Neurol 2023; 30(10):3367-3376.

8. Cacciaguerra L, Redenbaugh V, Chen JJ, Morris P, **Sechi E**, Syc-Mazurek SB, Lopez-Chiriboga AS, Tillema JM, Rocca MA, Filippi M, Pittock SJ, Flanagan EP. *Timing and Predictors of T2-Lesion Resolution in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease*. *Neurology* 2023; 101(13):e1376-e1381.
9. Elsbernd P, Cacciaguerra L, Krecke KN, Chen JJ, Gritsch D, Lopez-Chiriboga AS, **Sechi E**, Redenbaugh V, Morris PP, Carter JL, Wingerchuk DM, Tillema JM, Valencia-Sanchez C, Thakolwiboon S, Pittock SJ, Flanagan EP. *Cerebral enhancement in MOG antibody-associated disease*. *J Neurol Neurosurg Psychiatry* 2023; doi: 10.1136/jnnp-2023-331137.
10. Redenbaugh V, Chia NH, Cacciaguerra L, McCombe JA, Tillema JM, Chen JJ, Lopez Chiriboga AS, **Sechi E**, Hacohen Y, Pittock SJ, Flanagan EP. *Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS*. *Mult Scler* 2023; 29(7):799-808.
11. Webb LM, Cacciaguerra L, Krecke KN, Chen JJ, **Sechi E**, Redenbaugh V, Dubey D, Pittock SJ, Flanagan EP. *Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS*. *J Neurol Sci* 2023; doi: 10.1016/j.jns.2023.120687.
12. Valencia-Sanchez C, **Sechi E**, Dubey D, Flanagan EP, McKeon A, Pittock SJ, Zekeridou A. *Immune checkpoint inhibitor-associated central nervous system autoimmunity*. *Eur J Neurol* 2023; 30(8):2418-2429.
13. Dinoto A, Zara P, Mariotto S, Ferrari S, Flanagan EP, Budhram A, Orellana D, Turilli D, Solla P, Day GS, **Sechi E**, Lopez-Chiriboga AS. *Autoimmune encephalitis misdiagnosis and mimics*. *J Neuroimmunol* 2023; doi: 10.1016/j.jneuroim.2023.578071.
14. **Sechi E**, Defazio G, Erre GL, Solla P. *Author Response: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis*. *Neurology*. 2023 Feb 7;100(6):311-312. doi: 10.1212/WNL.000000000206851.
15. Cacciaguerra L, Morris P, Tobin WO, Chen JJ, Banks SA, Elsbernd P, Redenbaugh V, Tillema JM, Montini F, **Sechi E**, Lopez-Chiriboga AS, Zalewski N, Guo Y, Rocca MA, Filippi M, Pittock SJ, Lucchinetti CF, Flanagan EP. *Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder*. *Neurology*. 2023 Jan 23;10.1212/WNL.000000000206820. doi: 10.1212/WNL.000000000206820.
16. Carta S, Cobo Calvo Á, Armangué T, [...] **Sechi E**, Flanagan EP, Pittock SJ, Redenbaugh V, Reindl M, Marignier R, Mariotto S. *Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study*. *Neurology*. 2022 Dec 16;10.1212/WNL.000000000201662. doi: 10.1212/WNL.000000000201662.
17. Fadda G, Flanagan EP, **Sechi E**. *Editorial: Immune-mediated disorders of the spinal cord: Diagnosis, treatment strategies, and outcomes in the 21st century*. *Front Neurol*. 2022 Nov 29;13:1087631. doi: 10.3389/fneur.2022.1087631.
18. Filippi M, Preziosa P, Arnold DL, Barkhof F, Harrison DM, Maggi P, Mainero C, Montalban X, **Sechi E**, Weinschenker BG, Rocca MA. *Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective*. *J Neurol*. 2023 Mar;270(3):1286-1299.
19. Fadda G, Flanagan EP, Cacciaguerra L, Jitrapaikulsan J, Solla P, Zara P, **Sechi E**. *Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD*. *Front Neurol* 2022. doi: 10.3389/fneur.2022.1011579.
20. Valencia-Sanchez C, Guo Y, Krecke KN, Chen JJ, Redenbaugh V, Montalvo M, Elsbernd PM, Tillema JM, Lopez-Chiriboga S, Budhram A, **Sechi E**, et al. *Cerebral cortical encephalitis in*

MOGAD. Ann Neurol 2022. doi: 10.1002/ana.26549.

21. Cacciaguerra L, **Sechi E**, Rocca MA, Filippi M, Pittock SJ, Flanagan EP. *Neuroimaging features in inflammatory myelopathies: A review*. Front Neurol 2022. doi: 10.3389/fneur.2022.993645.
22. Spagni G, Sun B, Monte G, **Sechi E**, Iorio R, Evoli A, Damato V. *Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis*. J Neurol Neurosurg Psychiatry 2022. doi: 10.1136/jnnp-2022-330086.
23. Syc-Mazurek S, Chen JJ, Morris P, **Sechi E**, et al. *Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease*. Neurology 2022. doi: 10.1212/WNL.0000000000201263.
24. **Sechi E**, Cacciaguerra L, Chen JJ, et al. *Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI features, Diagnosis, and Management*. Front Neurol 2022. doi: 10.3389/fneur.2022.885218.
25. **Sechi E**, Gallus E, Solla P, et al. *Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis*. Neurology 2022. doi: 10.1212/WNL.0000000000200837.
26. Dinoto A, Gastaldi M, Iorio R, Marini S, Damato V, Farina A, Zoccarato M, **Sechi E**, et al. *Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders*. Mult Scler Relat Disord. 2022 Apr 25;63:103827. doi: 10.1016/j.msard.2022.103827.
27. Dinoto A, **Sechi E**, Flanagan EP, Ferrari S, Solla P, Mariotto S, Chen JJ. *Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease*. Front Neurol. 2022 Mar 23;13:866824. doi: 10.3389/fneur.2022.866824.
28. Dinoto A, **Sechi E**, Ferrari S, et al. *Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD*. Mult Scler Relat Disord 2022. doi: 10.1016/j.msard.2021.103424.
29. Solla P, Ercoli T, Masala C, Orofino G, Fadda L, Corda DG, Zarbo IR, Meloni M, **Sechi E**, Bagella CF, Defazio G. *Rasagiline Withdrawal Syndrome in Parkinson's Disease*. Brain Sci. 2022; 12(2):219. doi: 10.3390/brainsci12020219.
30. Barakat B, Messina S, Nayak S, Kassa R, **Sechi E**, et al. *Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions*. Mult Scler J Exp Transl Clin. 2022 Jan 12;8(1):20552173211052159. doi: 10.1177/20552173211052159.
31. Bagella CF, Corda DG, Zara P, Elia AE, Ruiu E, **Sechi E**, Solla P. *Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination*. Vaccines (Basel). 2021 Dec 19;9(12):1502.
32. Redenbaugh V, Montalvo M, **Sechi E**, et al. *Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders*. Mult Scler J Exp Transl Clin. 2021 Nov 26;7(4):20552173211052656. doi: 10.1177/20552173211052656.
33. Dominguez L, Collazo IVM, **Sechi E**, Bohm P, Chiriboga SL. *Neurochondrin immunoglobulin G - Associated myelopathy - Ataxia syndrome*. J Neurol Sci. 2022; 432:120058. doi: 10.1016/j.jns.2021.120058.

34. Rodriguez A, Klein CJ, **Sechi E**, et al. *LG11 antibody encephalitis: acute treatment comparisons and outcome*. J Neurol Neurosurg Psychiatry. 2022;93(3):309-315.
35. Zara P, Floris V, Flanagan EP, Lopez-Chiriboga AS, Weinschenker BG, Solla P, **Sechi E**. *Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI*. Mult Scler J Exp Transl Clin. 2021 Nov 19;7(4):20552173211048761. doi: 10.1177/20552173211048761.
36. Redenbaugh V, Flanagan EP, Floris V, [...] and **Sechi E**. *Exposure to TNF inhibitors is rare at MOGAD presentation*. J Neurol Sci. 2022 Jan 15;432:120044. doi: 10.1016/j.jns.2021.120044. Epub 2021 Oct 27.
37. **Sechi E**, Flanagan EP. *Evaluation and Management of Acute Myelopathy*. Semin Neurol. 2021 Oct;41(5):511-529.
38. Arru G, Galleri G, Deiana GA, Zarbo IR, **Sechi E**, et al. *HERV-K Modulates the Immune Response in ALS Patients*. Microorganisms. 2021 Aug 23;9(8):1784.
39. Zhao-Fleming HH, Valencia Sanchez C, **Sechi E**, et al. *CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies*. Neurology. 2021 Sep 28;97(13):e1351-e1358.
40. **Sechi E**, Flanagan EP. *Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management*. Front Neurol. 2021 Jul 7;12:673339. doi: 10.3389/fneur.2021.673339. eCollection 2021.
41. **Sechi E**, Zarbo R, Biancu MA, et al. *Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder*. J Neuroimmunol. 2021 Sep 15;358:577666. doi: 10.1016/j.jneuroim.2021.577666. Epub 2021 Jul 18.
42. **Sechi E**, Krecke KN, Messina SA, et al. *Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders*. Neurology. 2021 Sep 14;97(11):e1097-e1109.
43. **Sechi E**, Buciu M, Pittock SJ, et al. *Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing*. JAMA Neurol. 2021 Jun 1;78(6):741-746.
44. Banks SA, **Sechi E**, Flanagan EP. *Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression*. Ther Adv Neurol Disord. 2021; doi: 10.1177/1756286421998906. eCollection 2021.
45. Budhram A, **Sechi E**, Flanagan EP, et al. *Clinical spectrum of high-titre GAD65 antibodies*. J Neurol Neurosurg Psychiatry. 2021 Feb 9;jnnp-2020-325275. doi: 10.1136/jnnp-2020-325275. Online ahead of print.
46. Mustafa R, Passe TJ, Lopez-Chiriboga AS, Weinschenker BG, Krecke KN, Zalewski NL, Diehn FE, **Sechi E**, [...] Flanagan EP. *Utility of MRI Enhancement Pattern in Myelopathies with Longitudinally-extensive T2-lesions*. Neurol Clin Pract 2021; First published January 25, 2021, DOI: <https://doi.org/10.1212/CPJ.000000000001036>.
47. **Sechi E**, Mariotto S, McKeon A, et al. *Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis*. Stroke. 2021 Jan;52(2):645-654. doi: 10.1161/STROKEAHA.120.031482. Epub 2021 Jan 11.
48. Banks SA, Morris PP, Chen JJ, Pittock SJ, **Sechi E**, et al. *Brainstem and cerebellar involvement in*

MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. 2020 Dec 28;jnnp-2020-325121. doi: 10.1136/jnnp-2020-325121. Online ahead of print.

49. **Sechi E**, Buciu M, Flanagan EP, et al. *Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder.* Mult Scler Relat Disord. 2021 Jan;47:102638. doi: 10.1016/j.msard.2020.102638. Epub 2020 Nov 23.
50. Budhram A, Dubey D, **Sechi E**, et al. *Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis.* Clin Chem. 2020 Nov 22;hvaa254. doi: 10.1093/clinchem/hvaa254. Online ahead of print.
51. **Sechi E**, Zekeridou A. *Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.* J Thorac Oncol. 2021 Mar;16(3):381-394. doi: 10.1016/j.jtho.2020.11.005. Epub 2020 Nov 11.
52. Berti A, Moura MC, **Sechi E**, et al. *Beyond Giant Cell Arteritis and Takayasu's Arteritis: Secondary Large Vessel Vasculitis and Vasculitis Mimickers.* Beyond Giant Cell Arteritis and Takayasu's Arteritis: Secondary Large Vessel Vasculitis and Vasculitis Mimickers. Curr Rheumatol Rep. 2020 Nov 7;22(12):88. doi: 10.1007/s11926-020-00965-w.
53. Sun MM, Seleme N, Chen JJ, Zekeridou A, **Sechi E**, [...] Gordon LK. *Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade.* J Neuroophthalmol. 2020 Oct 28. doi: 10.1097/WNO.0000000000001148. Online ahead of print.
54. Buciu M, **Sechi E**, Flanagan EP, Lopez-Chiriboga AS. *Unfavorable outcome in highly relapsing MOGAD encephalitis.* J Neurol Sci. 2020 Nov 15;418:117088. doi: 10.1016/j.jns.2020.117088. Epub 2020 Aug 10.
55. Lopez-Chiriboga AS, **Sechi E**, Buciu M, et al. *Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder.* JAMA Neurol. 2020 Aug 31;77(12):1575-1577. doi: 10.1001/jamaneurol.2020.3115. Online ahead of print.
56. Nayak S, **Sechi E**, Flanagan EP, et al. *Inflammatory activity following motor progression due to critical CNS demyelinating lesions.* Mult Scler. 2020 Aug 19;1352458520948745. doi: 10.1177/1352458520948745. Online ahead of print.
57. **Sechi E**, Markovic SN, McKeon A, et al. *Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.* Neurology. 2020 Oct 27;95(17):e2442-e2452. doi: 10.1212/WNL.0000000000010632. Epub 2020 Aug 13.
58. Kassa RM, **Sechi E**, Flanagan EP, et al. *Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions.* Mult Scler. 2020 Jul 15;1352458520940983. doi: 10.1177/1352458520940983. Online ahead of print.
59. Mariotto S, **Sechi E**, Ferrari S. *Serum neurofilament light chain studies in neurological disorders, hints for interpretation.* J Neurol Sci. 2020 Sep 15;416:116986. doi: 10.1016/j.jns.2020.116986. Epub 2020 Jun 14.
60. Budhram A, **Sechi E**, Nguyen A, et al. *FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis With Seizures (FLAMES): Is immunotherapy always needed to put out the fire?* Mult Scler Relat Disord. 2020 Sep;44:102283. doi: 10.1016/j.msard.2020.102283. Epub 2020 Jun 11
61. **Sechi E**, Messina S, Keegan BM, et al. *Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.* Mult Scler 2021 Apr;27(5):667-673. doi: 10.1177/1352458520929192. Epub 2020 Jun 18.

62. Orlandi R, Mariotto S, Ferrari S, Gobbin F, **Sechi E**, [...] Gajofatto A. *Diagnostic features of initial demyelinating events associated with serum MOG-IgG*. J Neuroimmunol 2020 Jul 15;344:577260. doi: 10.1016/j.jneuroim.2020.577260. Epub 2020 May 7.
63. **Sechi E**, Flanagan EP. *Spinal arteriovenous fistula's often misdiagnosed as myelitis; can we stem the flow?* J Neurol Sci. 2020 Jun 15;413:116868. doi: 10.1016/j.jns.2020.116868. Epub 2020 Apr 30.
64. **Sechi E**, Krecke, KN, Pittock SJ, et al. *Frequency and Characteristics of MRI-Negative Myelitis Associated with MOG Autoantibody*. Mult Scler 2021 Feb;27(2):303-308.
65. Arru G, **Sechi E**, Mariotto S, et al. *Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD*. J Neuroimmunol. 2020 Jan 15;338:577110. doi: 10.1016/j.jneuroim.2019.577110.
66. Asnafi S, Morris PP, **Sechi E**, et al. *The frequency of longitudinally extensive transverse myelitis in MS: A population-based study*. Mult Scler Relat Disord. 2019 Oct 31;37:101487. doi: 10.1016/j.msard.2019.101487.
67. Lapedda AJ, Deiana GA, Lobina O, Nieddu G, Balduin P, De Muro P, Andreetta F, **Sechi E**, Arru G, Corda DG, Sechi GP, Formato M. *Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential*. J Circ Biomark. 2019 Sep 11;8:1849454419875912. doi: 10.1177/1849454419875912.
68. **Sechi E**, Keegan BM, Kaufmann TJ, Kantarci OH, Weinshenker BG, Flanagan EP. *Unilateral Motor Progression in MS: Association with a Critical Corticospinal Tract Lesion*. Neurology 2019, in press.
69. Mariotto S, Gajofatto A, Zuliani L, [...] **Sechi E**, Monaco S, Ferrari S. *Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis*. J Neurol 2019. <https://doi.org/10.1007/s00415-019-09306-z>.
70. **Sechi E**, Shosha E, Williams JP, Pittock SJ, Weinshenker BG, Keegan BM, Zalewski NL, Lopez-Chiriboga AS, Jitprapaikulsan J, Flanagan EP. *Aquaporin-4 and MOG Autoantibody Discovery in Idiopathic Transverse Myelitis Epidemiology*. Neurology 2019, in press.
71. Mariotto S, Ferrari S, Gastaldi M, Franciotta D, **Sechi E**, et al. *Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders*. J Neurol Neurosurg Psychiatry 2019, in press.
72. **Sechi E**, Flanagan EP. *Diagnosis and Management of Autoimmune Dementia*. Curr Treat Options Neurol 2019;21(3):11.
73. **Sechi E**, Parks NE, Koeller KK, Flanagan EP. *Hypertrophic Olivary Degeneration Mimics Relapse in Neuromyelitis Optica Spectrum Disorder*. Neurology 2019;92(7):343-344.
74. **Sechi E**, Flanagan EP. *Area postrema syndrome in autoimmune GFAP astrocytopathy*. Mult Scler 2019. doi: 10.1177/1352458519826489. [Epub ahead of print].
75. Dubey D, Pittock SJ, Krecke KN, Morris PP, **Sechi E**, [...] Flanagan EP. *Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody*. JAMA Neurol. Published online December 21, 2018. doi:10.1001/jamaneurol.2018.4053.
76. **Sechi E**, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Aksamit AJ, [...]

Zekeridou A, Wingerchuk DM, Jitrapaikulsan J, Flanagan EP. *Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis*. J Neurol Neurosurg Psychiatry 2018 Jul 21. pii: jnnp-2018-318004. doi: 10.1136/jnnp-2018-318004.

77. **Sechi E**, Keegan BM, Flanagan EP. *Applying the 2017 McDonald diagnostic criteria for multiple sclerosis*. Lancet Neurol. 2018 Jun;17(6):498-499.
78. Arru G, Mameli G, Deiana GA, Rassu AL, Piredda R, **Sechi E**, [...] Sechi LA. *Humoral immunity response to human endogenous retroviruses K/W differentiates between amyotrophic lateral sclerosis and other neurological diseases*. Eur J Neurol. 2018 Mar 31. doi: 10.1111/ene.13648. [Epub ahead of print]
79. Bo M, Niegowska M, Arru G, **Sechi E**, [...] Sechi LA. *Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder*. J Neuroimmunol. 2018 May 15;318:97-102.
80. Arru G, **Sechi E**, Mariotto S, [...] Mameli G, Sechi LA, Sechi G. *Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder*. Mult Scler J Exp Transl Clin (Accepted for publication Oct 2017).
81. Mariotto S, Ferrari S, Monaco S, [...] **Sechi E**, Urso D, Delogu R, Janes F, Deotto L, Cadaldini M, Bianchi MR, Cantalupo G, Reindl M, Gajofatto A. *Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study*. J Neurol (Accepted for publication Oct 2017).
82. **Sechi E**, Addis A, Batzu L, Mariotto S, Ferrari S, Conti M, Sechi G. *Late presentation of NMOSD as rapidly progressive leukoencephalopathy with atypical clinical and radiological findings*. Mult Scler First published date: August-17-2017; doi: 10.1177/1352458517721661.
83. Doneddu PE, **Sechi E**, Addis A, Fadda G, Fois C, Sechi G. *Cranial Nerve Involvement in Neuralgic Amyotrophy*. J Neurol Neurophysiol 2016; 7:399.
84. Fois C, Rassu AL, Mandia D, **Sechi E**, Doneddu PE, Sechi G. *Paradoxical Effect of Levetiracetam in Newly Diagnosed Type II Focal Cortical Dysplasia*. Clin Neuropharmacol 2016; 39(5):265-268.
85. Sechi G, **Sechi E**, Fois C, Kumar N. *Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults*. Nutr Rev 2016; 74(5):281-300.
86. **Sechi E**, Addis A, Piredda R, Rassu AL, Mameli G, Senes C, Sechi G. *Longitudinally Extensive Spinal Cord Lesions Disclosing Occult Systemic Sarcoidosis*. JAMA Neurol 2016; 73(5):600-601.
87. Doneddu PE, **Sechi E**, Addis A, Fadda G, Fois C, Sechi G. *Neuralgic amyotrophy mimicking Vernet syndrome*. J Neurol Sci 2016; 362:230-231.
88. Fancellu L, Borsini W, Romani I, Pirisi A, Deiana GA, **Sechi E**, Doneddu PE, Rassu AL, Demurtas R, Scarabotto A, Cassini P, Arbustini E, Sechi G. *Exploratory screening for Fabry's disease in young adults with cerebrovascular disorders in northern Sardinia*. BMC Neurol 2015; 15:256.
89. **Sechi E**, Addis A, Fadda G, Minafra L, Bravatà V, Sechi G. *Teaching NeuroImages: Subacute encephalopathy in a young woman with THTR2 gene mutation*. Neurology 2015; 85(14):e108-109.
90. Sechi G, Fois C, Addis A, **Sechi E**. *Clinicopathologic features of folate-deficiency neuropathy*. Neurology 2015; 85(12):1090-1091.

91. Sechi G, **Sechi E**. *Restless legs syndrome and cerebrovascular disease*. *Lancet Neurol* 2013; 12(8):734.
92. Sechi G, Ceccherini I, Bachetti T, Deiana GA, **Sechi E**, Balbi P. *Ceftriaxone for Alexander's Disease: A Four-Year Follow-Up*. *JIMD Rep* 2013; 9:67-71.
93. Carai A, Fenu G, **Sechi E**, Crotti FM, Montella A. *Anatomical variability of the lateral femoral cutaneous nerve: findings from a surgical series*. *Clin Anat* 2009; 22(3):365-370.

Abstract e presentazioni orali a congressi e conferenze internazionali

1. **Sechi E**, et al. *Epidemiology of Aquaporin-4-IgG positive Neuromyelitis Optica Spectrum Disorder in Sardinia*. ECTRIMS 2023 Milan. Poster (P057).
2. **Sechi E**. *Diagnosis and Treatment of Central Nervous System Autoimmunity from Immune Checkpoint Inhibitors*. 75th Meeting of the American Academy of Neurology; Boston 2023. Invited talk.
3. **Sechi E**. *Discussion of challenging cases*. Autoantibodies in Central and Peripheral Nervous System Disorders. (Verona March 25th 2022). Invited talk.
4. **Sechi E**. *Neurological complications of immunotherapies in oncology: Checkpoint inhibitors*. Neuroimmunology group 2021 - IMMUNOMEDIATE DISEASES OF THE NERVOUS SYSTEM: RECENT ADVANCES (Florence December 3th-4th). Invited talk.
5. **Sechi E**. *MOGAD. MAGNETIC RESONANCE TECHNIQUES IN MULTIPLE SCLEROSIS* - Twenty-third Advanced Course (Milan 3-4 November 2021). Invited talk.
6. **Sechi E**, Buciu M, Pittok SJ, et al. *The Positive Predictive Value of MOG Autoantibody Live Cell-Based Assay in a Tertiary Referral Center (4224)*. 73rd Meeting of the American Academy of Neurology; San Francisco 2021 (Virtual). Platform presentation.
7. Montalvo M, Pittock SJ, **Sechi E**, et al. *The Positive Predictive Value of Aquaporin-4 Antibody Live Cell-based Assay in a Tertiary Referral Center (1648)*. 73rd Meeting of the American Academy of Neurology; San Francisco 2021 (Virtual). Platform presentation.
8. **Sechi E**, Krecke K, Buciu M, et al. *Lesion Evolution on MRI in Myelitis Associated with MS, Aquaporin-4-IgG and Myelin Oligodendrocyte Glycoprotein-IgG (4913)*. 72nd Meeting of the American Academy of Neurology; Toronto 2020 (Virtual). Platform presentation.
9. **Sechi E**, Markovic SN, McKeon A, et al. *Neurological Complications and Neural Autoantibody Profiles Associated with Immune Checkpoint Inhibitors (4215)*. 72nd Meeting of the American Academy of Neurology; Toronto 2020 (Virtual). Platform presentation.
10. Zivelonghi C, McKeon A, **Sechi E**, et al. *AMPA Autoimmunity: Neurological, Oncological and Serological Accompaniments. (4689)*. 72nd Meeting of the American Academy of Neurology; Toronto 2020 (Virtual).
11. Kassa RM, **Sechi E**, Flanagan EP, et al. *Onset of Progressive Motor Impairment in Patients with Critical CNS Demyelinating Lesions (4405)*. 72nd Meeting of the American Academy of Neurology; Toronto 2020 (Virtual).
12. Zalewski NL, **Sechi E**, McKeon A, et al. *Serum Neurofilament Light Chain Levels Differentiate Spinal Cord Infarction from Inflammatory Myelitis (2620)*. 72nd Meeting of the American Academy of

Neurology; Toronto 2020 (Virtual).

13. Lopez-Chiriboga AS, **Sechi E**, Buciu M, et al. *Long term outcomes in Myelin Oligodendrocyte Glycoprotein-IgG (MOG-IgG) Associated Disorders (1906)*. 72nd Meeting of the American Academy of Neurology; Toronto 2020 (Virtual). Platform presentation.
14. **Sechi E**, Messina S, Keegan BM, et al. A population-based comparison of cervical spine corticospinal tract lesions in benign and secondary progressive MS. ECTRIMS 2019 Stockholm. Poster (P1114).
15. **Sechi E**, Shosha E, Williams JP, Pittock SJ, Weinshenker BG, Keegan BM, Zalewski NL, Lopez-Chiriboga AS, Jitrapaikulsan J, Flanagan EP. *A Population-Based Study of Idiopathic Transverse Myelitis with Aquaporin-4-IgG and Myelin-Oligodendrocyte-Glycoprotein-IgG Assessment (S11.007)*. 71st Meeting of the American Academy of Neurology; Philadelphia 2019. Platform presentation.
16. **Sechi E**, Keegan BM, Kaufmann T, et al. *Unilateral Motor Progression in Multiple Sclerosis: Association with a Single Critical Corticospinal Tract Lesion (P5.2-012)*. 71st Meeting of the American Academy of Neurology; Philadelphia 2019. Poster presentation.
17. Asnafi S, Morris PP, Pittock SJ, Weinshenker BG, Palace J, Messina S, **Sechi E**, Flanagan EP. *The Frequency of Longitudinally Extensive Transverse Myelitis in Multiple Sclerosis in the Era of Glial Biomarkers; A Population-Based Study (P4.2-055)*. 71st Meeting of the American Academy of Neurology; Philadelphia 2019. Poster presentation.
18. **Sechi E**, Keegan BM, Kaufmann TJ, Kantarci OH, Weinshenker BG, Flanagan EP. *Unilateral motor progression in multiple sclerosis: the impact of single critical corticospinal tract lesions*. ECTRIMS 2018 Berlin. Poster (P460).
19. Mariotto S, Ferrari S, Gastaldi M, Franciotta D, **Sechi E**, [...] Gajofatto A. *Neurofilament light chain serum concentration reflects disease severity in patients with MOG-Ab associated disorders*. ECTRIMS 2018 Berlin. Poster (P1173).
20. **Sechi E**, Morris PP, McKeon A, [...] Flanagan EP. *Glial Fibrillary Acid Protein Immunoglobulin G (GFAP-IgG) Related Myelitis: Characterization and Comparison with Aquaporin-4-IgG Myelitis (S13.006)*. 70th AAN Meeting, Los Angeles 2018. Platform presentation.
21. Batzu L, **Sechi E**, Frau C, Mamei G, Ortu R, Sechi G. *Atopic Myelitis: a new European case of a probably underestimated disorder*. 3rd Congress of the European Academy of Neurology; Amsterdam 2017. ePresentation: PR3104.
22. Demurtas R, Boadu W, **Sechi E**, Mandia D, Delogu R, Corda D, Sechi G. *Acute, progressive aquaporin-4 antibodies encephalopathy mimicking herpes simplex encephalitis*. 3rd Congress of the European Academy of Neurology; Amsterdam 2017. Poster: POD505.
23. Fois C, Rassu AL, **Sechi E**, Addis A, Piredda R, Demurtas R, Mandia D, Sechi G. *Unpredictable seizure-worsening induced by Levetiracetam monotherapy in a patient with focal cortical dysplasia type II*. 2nd Congress of the European Academy of Neurology; Copenhagen 2016. Poster: P11131.
24. Rassu AL, Piredda R, Addis A, **Sechi E**, Fois C, Boadu W, Nako E, Sechi G. *Recurrence of Herpes Simplex Encephalitis after 16 years*. 2nd Congress of the European Academy of Neurology; Copenhagen 2016. Poster: P32091.
25. Piredda R, **Sechi E**, Rassu AL, Addis A, Urso D, Fois C, Ortu R, Sechi G. *Late Onset Atypical Pantothenate-Kinase Associated Neurodegeneration with Homozygous PANK2 mutation in three Sardinian Siblings*. 2nd Congress of the European Academy of Neurology; Copenhagen 2016. Poster: P31124.

26. Addis A, Rassu AL, **Sechi E**, Piredda R, Agrò L, Fois C, Corda DG, Sechi G. *Autoimmune encephalitis in a patient with benign pancreatic neoplasia*. 2nd Congress of the European Academy of Neurology; Copenhagen 2016. Poster: P11221.
27. **Sechi E**, Addis A, Piredda R, Rassu AL, Fois C, Batzu L, Sechi G. *Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) with extensive neurologic involvement and neutrophilia*. 2nd Congress of the European Academy of Neurology; Copenhagen 2016. Poster: P32216.
28. Addis A, **Sechi E**, Rassu AL, Piredda R, Sechi GP. *ID 411 – Diffuse hyperpathia in a case of Wernicke’s-like encephalopathy*. 15th European Congress on Clinical Neurophysiology, Brno. Clin Neurophysiol 2016; 127(3):e64–e65.
29. Rassu AL, Fois C, **Sechi E**, Piredda R, Murrighile RM, Porcella V, Sechi GP. *ID 332 – Possible cause of autoimmune encephalopathy in epileptic patient*. 15th European Congress on Clinical Neurophysiology, Brno. Clin Neurophysiol 2016; 127(3):e86.

Abstract e presentazioni orali a congressi e conferenze nazionali

1. **Sechi E**. *MOGAD: Who, When and How to treat?* IX NaplesMeeting. Napoli 2023. Invited talk.
2. **Sechi E**. *Fisiopatologia di MG e NMOSD: il ruolo centrale del complemento*. CORNER – II Complemento nelle malattie rare neurologiche – Expert Meeting, Focus NMOSD & MG. (Cagliari; 14 luglio 2023). Invited talk.
3. **Sechi E**. *Mieliti: Nuove prospettive - Aspetti radiologici delle mieliti* – 52nd Congress of the Italian Neurological Society (Milano, December 3-6 2022). Invited talk.
4. **Sechi E**. *Epidemiologia della MG*. CORNER – II Complemento nelle malattie rare neurologiche – Expert Meeting, Focus MG. (Roma, November 10th 2022). Invited talk.
5. **Sechi E**. *Valore predittivo e “falsi positivi” nella diagnostica di NMOSD e MOGAD*. 3° Corso di Diagnostica di laboratorio delle malattie Demielinizzanti. (Alghero, October 7-8 2022). Invited talk.
6. **Sechi E**. *Depressione nelle patologie neurologiche autoimmuni*. MALATTIE NEUROLOGICHE E DEPRESSIONE. DALLA CLINICA AL TRATTAMENTO (Sassari 26 November 2021). Invited talk.
7. Rassu AL, Fois C, Piredda R, **Sechi E**, Addis A, Sechi GP, Corda D. *L’epilessia nelle cromosomopatie 4p: ruolo di Levetiracetam e Carbamazepina*. 39° Congresso Nazionale LICE, Roma 2016. Poster presentation.
8. Fois C, Rassu AL, **Sechi E**, Mandia D, Sechi GP. *Effetto paradossale da levetiracetam in paziente con displasia corticale focale tipo II*. 39° Congresso Nazionale LICE, Roma 2016. Poster presentation.
9. Fancellu L, Pirisi A, **Sechi E**, Mandia D, Sechi G. *Fabry disease in Sardinia: need for a multidisciplinary approach*. XLV Congresso Società Italiana di Neurologia, Cagliari 2014. Poster presentation.
10. Doneddu PE, **Sechi E**, Addis A, Sechi G. *Ceftriaxone for Alexander’s disease: a four years follow-up*. XLV Congresso Società Italiana di Neurologia, Cagliari 2014. Poster presentation.
11. **Sechi E**, Doneddu PE, Addis A, Sechi G. *Neuralgic amyotrophy presenting as a Vernet’s syndrome: a case report*. XLV Congresso Società Italiana di Neurologia, Cagliari 2014. Poster presentation.

Libri, capitoli di libro e altro

1. **Sechi E**, Dean M. Wingerchuk. *Case 2: Rapidly progressive numbness and weakness after soft-tissue abscess*. Mayo Clinic Cases in Neuroimmunology. Edited by McKeon A, Keegan BM, and Tobin WO. Oxford University Press; Jan 18 2022.
2. **Sechi E**, Flanagan EP. *Case 39: Progressive quadriparesis and cancer*. Mayo Clinic Cases in Neuroimmunology. Edited by McKeon A, Keegan BM, and Tobin WO. Oxford University Press; Jan 18 2022.
3. **Sechi E**, Flanagan EP. *Autoimmune Demyelinating Syndromes: Aquaporin-4-IgG-positive NMOSD and MOG - IgG Associated Disorder; Chapter 15*. Piquet AL, Alvarez E (eds.) *Neuroimmunology* (Springer Nature Switzerland AG 2021); http://doi.org/10.1007/978-3-030-61883-4_15
4. Sechi G, Fancellu L, Doneddu P and **Sechi E**. *Wernicke–Korsakoff Syndrome*. In: eLS. John Wiley & Sons Ltd, Chichester. 2014; <http://www.els.net> [doi: 10.1002/9780470015902.a0025810]
5. Carai A, Fenu G, **Sechi E** (illustrations). *Approcci chirurgici al basicranio*. Aracne editrice 2010. ISBN: 978-88-548-3228-2.

Fondi di ricerca e premi

1. **Fondo di ricerca “Fondo Giancesini” – 2019/2020 VI Edizione**
Progetto: “Neurofilamenti sierici a catena leggera e specifici pattern di risonanza magnetica come biomarcatori per la diagnosi precoce di mielopatia acuta e predizione di disabilità”
2. **ECTRIMS Travel Grant – Stockholm 2019**
Project: “A population-based comparison of cervical spine corticospinal tract lesions in benign and secondary progressive MS”.
3. **Annual Symposium of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology: “Innovative approaches to the diagnosis and treatment of MS and autoimmune neurologic disorders”– 1st Place Poster Session**
Project: “Neurological Complications and Neural Autoantibody Profiles Associated with Immune Checkpoint Inhibitors”
4. **ECTRIMS Travel Grant – Berlin 2018**
Project: “Unilateral motor progression in multiple sclerosis: the impact of single critical corticospinal tract lesions”.
5. **Postdoctoral Fellowship Award - Translational Clinical (27/6/2018-26/6/2019)**
Project: “Defining the clinical and radiologic spectrum of spinal cord involvement of CNS demyelinating disease and assessing its importance in diagnosis and pathophysiology”
Funded by the Mayo Clinic Center for MS and Autoimmune Neurology.

Revisore per riviste internazionali

Annals of Neurology; Clinical Neurology and Neurosurgery; Critical Reviews in Clinical Laboratory Sciences; European Journal of Neurology; Frontiers in Neurology; Multiple Sclerosis and Related Disorders; Multiple Sclerosis Journal; Multiple Sclerosis Journal – Experimental, Translational and Clinical; Nature Reviews Neurology; Neurology; Journal of Alzheimer’s Disease; Journal of Neuroimmunology; Journal of Neurology; Journal of Neurology, Neurosurgery and Psychiatry;

Journal of the Neurological Sciences.

Membro di board editoriali o scientifici

1. Associate Editor – Multiple Sclerosis and Neuroimmunology
Frontiers Neurology
2. Medical Advisory Council
The MOG Project



Elia Sechi